The 4th Musketeer: Incorporating In-House PD-L1 Testing for Triple Negative Breast Cancer
Wednesday March 20th, 2024 at 2 pm ET
Speaker
Emina Torlakovic MD, PhD, FCAP
Saskatoon, Saskatchewan
Founder and Director, Canadian Biomarker Quality Assurance
Head, Division of Hematopathology, Saskatchewan Health Authority
Professor, Pathology and Laboratory Medicine, University of Saskatchewan
Dr. Emina Emilia Torlakovic obtained her M.D. at the University of Zagreb Medical School and her Ph.D. at the University of Oslo Medical School. She is board certified by The American Board of Pathology in Anatomic and Clinical Pathology with subspecialty boards in Hematopathology. She is a professor at the Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan. She is a Division Head of Hematopathology, Saskatchewan Health Authority. She was a founding member of the NordiQC, has co-founded CIQC, and most recently founded Canadian Biomarker Quality Assurance (CBQA) as well as CBQAReadout.ca (inter)national academic quality assurance programs, which she is currently directing. Dr. Torlakovic is the Chair of the National Standards Committee for High Complexity Testing of the Canadian Association of Pathologists. She is the President of the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) and a Board Member of the International Quality Network for Pathology (IQN Path). She is also currently leading several projects related to national and global standardization of clinical IHC applications.
Learning Objectives
- Summarize 2 approaches that can be utilized by clinical laboratories to implement fit-for-purpose PD-L1 testing for TNBC patients
- Describe the quality requirements for the implementation and maintenance of fit-for-purpose PD-L1 assays for TNBC patients